B7-H3: A promising therapeutic target for autoimmune diseases

Cell Immunol. 2020 Jun:352:104077. doi: 10.1016/j.cellimm.2020.104077. Epub 2020 Feb 21.

Abstract

B7-H3 as a newly identified costimulatory molecule that belongs to B7 ligand family, is broadly expressed in both lymphoid and non-lymphoid tissues. The overexpression of B7-H3 has been verified to be correlated with the poor prognosis and poor clinical outcome of several human cancers. In recent years, researchers reveal that B7-H3 is involved in the pathogenesis of various autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), Sjögren's syndrome (SS), ankylosing spondylitis (AS), etc. In this review, we will discuss the biological function of B7-H3 and summarize the progress made over past years regarding its role in the occurrence and development of autoimmune diseases. The insights gained from these findings could serve as the foundation for future therapies of these diseases.

Keywords: Autoimmune diseases; B7-H3; Costimulatory molecule; Therapeutic target.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / therapy
  • B7 Antigens / immunology*
  • B7 Antigens / metabolism*
  • Humans

Substances

  • B7 Antigens
  • CD276 protein, human